Fu-Zheng-Yi-Liu Formula inhibits the stem cells and metastasis of prostate cancer via tumor-associated macrophages/C-C motif chemokine ligand 5 pathway in tumor microenvironment

Abstract

Prostate cancer (PCa) is the second most common malignancy among men globally. The Fu-Zheng-Yi-Liu (FZYL) Formula has been widely utilized in the treatment of PCa. This study investigates whether the FZYL Formula can inhibit PCa by targeting the TAMs/CCL5 pathway. We conducted in vitro co-cultures and in vivo co-injections of PCa cells and TAMs to mimic their interaction. Results showed that the FZYL Formula significantly reduced the proliferation, colony formation, subpopulations of PCSCs, and sphere-formation efficacy of PCa cells, even in the presence of TAM co-culture. Additionally, the Formula markedly decreased the migration, invasion, and epithelial-mesenchymal transition (EMT) of PCa cells induced by TAMs. The FZYL Formula also reversed M2 phenotype polarization in TAMs and dose-dependently reduced their CCL5 expression and secretion, with minimal cytotoxicity observed. Mechanistic studies confirmed that the TAMs/CCL5 axis is a critical target of the FZYL Formula, as the addition of exogenous CCL5 partially reversed the formula’s inhibitory effects on PCSCs self-renewal in the co-culture system. Importantly, the Formula also significantly inhibited the growth of PCa xenografts, bone metastasis, and PCSCs activity in vivo by targeting the TAMs/CCL5 pathway. Overall, this study not only elucidates the immunomodulatory mechanism of the FZYL Formula in PCa therapy but also highlights the TAMs/CCL5 axis as a promising therapeutic target.

Keywords

Traditional Chinese medicine / Tumor-associated macrophages / Prostate cancer stem cells / CCL5 / Tumor microenvironment

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] Chen Z, Wang S, Bai Z, et al. Staging based strategies and practice for prostate cancer[J]. Chin J Integr Trad West Med, 2016, 36(6): 749-752.

[3] Darren JW, Andre KB, Virgilia M. PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer[J]. Nat Commun, 2017, 8(1): 1508.

[4] Harris KS, BA Kerr. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis[J]. Stem Cells Int, 2017, 2017: 8629234.

[5] Patel R, Fleming J, Mui E, et al. Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1[J]. EMBO Mol Med, 2018, 10(4): e8347.

[6] Huang H, Wang C, Liu F, et al. Reciprocal network between cancer stem-like cells and macrophages facilitates the progression and androgen deprivation therapy resistance of prostate cancer[J]. Clin Cancer Res, 2018, 24(18): 4612-4626.

[7] Maolake A, Izumi K, Shigehara K, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis[J]. Oncotarget, 2017, 8(6): 9739-9751.

[8] Wang S, Liu X, Huang R, et al. XIAOPI Formula inhibits breast cancer stem cells via suppressing tumor-associated macrophages/C-X-C motif chemokine ligand 1 pathway[J]. Front Pharmacol, 2019, 10: 1371.

[9] Wang S, Wang N, Huang X, et al. Baohuoside suppresses breast cancer metastasis by downregulating the tumor-associated macrophages/C-X-C motif chemokine ligand 1 pathway[J]. Phytomedicine, 2020, 78: 153331.

[10] Abrams DI. An integrative approach to prostate cancer[J]. J Altern Complement Med, 2018, 24(9-10): 872-880.

[11] Zhang Y, Lei B, Zou Q, et al. Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer[J]. National J Androl, 2017, 23(10): 922-927.

[12] Zhang B, Zheng Y, Zhao J, et al. Identification of multi-target anti-cancer agents from TCM Formula by in silico prediction and in vitro validation[J]. Chin J Nat Med, 2022, 20(5): 332-351.

[13] Huang Y, Zhu J, Lin X, et al. Potential of fatty oils from traditional Chinese medicine in cancer therapy: a review for phytochemical, pharmacological and clinical studies[J]. Am J Chin Med, 2019, 47(4): 727-750.

[14] Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24(5): 541-550.

[15] Chen TT, Du SL, Wang SJ, et al. Dahuang Zhechong Pills inhibit liver cancer growth in a mouse model by reversing Treg/Th1 balance[J]. Chin J Nat Med, 2022, 20(10): 102-110.

[16] Vitale I, Manic G, Coussens LM, et al. Macrophages and metabolism in the tumor microenvironment[J]. Cell Metab, 2019, 30(1): 36-50.

[17] Parisi L, Gini E, Baci D, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders?[J]. J Immunol Res, 2018, 2018: 8917804.

[18] Comito G, Giannoni E, Segura CP, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression[J]. Oncogene, 2014, 33(19): 2423-31.

[19] Hu W, Qian Y, Yu F, et al. Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma[J]. Oncol Lett, 2015, 10(3): 1390-1396.

[20] Wang N, Liu W, Zheng Y, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling[J]. Cell Death Dis, 2018, 9(9): 880.

[21] Nie Y, Huang H, Guo M, et al. Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy[J]. Clin Cancer Res, 2019, 25(13): 3873-3886.

[22] Mei W, Lin X, Kapoor A, et al. The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis[J]. Cancers (Basel), 2019, 11(4): 434.

[23] Huang R, Wang S, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling[J]. Cell Death Dis, 2020, 11(4): 234.

[24] Han J, Won M, Kim JH, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective[J]. Chem Soc Rev, 2020, 49(22): 7856-7878.

[25] Chen X, Li Q, Liu X, et al. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer[J]. Clin Cancer Res, 2016, 22(17): 4505-4516.

[26] Wang Z, Wang N, Li W, et al. Caveolin-1 mediates chemoresistance in breast cancer stem cells via beta-catenin/ABCG2 signaling pathway[J]. Carcinogenesis, 2014, 35(10): 2346-2356.

[27] Li Q, Ye L, Guo W, et al. PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway[J]. J Exp Clin Cancer Res, 2017, 36(1): 85.

[28] Gires O, Pan M, Schinke H, et al. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?[J]. Cancer Metastasis Rev, 2020, 39(3): 969-987.

[29] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84.

[30] Wang N, Wang S, Wang X, et al. Research trends in pharmacological modulation of tumor-associated macrophages[J]. Clin Transl Med, 2021, 11(1): e288.

[31] Aldinucci D, Borghese C. The CCL5/CCR5 axis in cancer progression[J]. Cancers (Basel), 2020, 12(7): 1765.

[32] Kjeldsen JW, M Donia, IM Svane. [ Cancer immunotherapy][J]. Ugeskr Laeger, 2018, 180(21): 2-6.

[33] Bansal D, MA Reimers, EM Knoche, et al. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer[J]. Cancers (Basel), 2021, 13(2):1-22.

[34] Wang T, Wu L, Wang S, et al. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer[J]. Chin J Nat Med, 2023, 21(5): 333-345.

[35] Liu JM, PH Lin, RJ Hsu, et al. Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer[J]. Medicine (Baltimore), 2016, 95(31): e4475.

[36] Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions[J]. Nat Rev Cancer, 2008, 8(10): 755-68.

[37] Hass R, von der Ohe J, Ungefroren H. Impact of the tumor microenvironment on tumor heterogeneity and consequences for cancer cell plasticity and stemness[J]. Cancers (Basel), 2020, 12(12):1-20.

[38] Vahidian F, Duijf PHG, Safarzadeh E, et al. Interactions between cancer stem cells, immune system and some environmental components: friends or foes?[J]. Immunol Lett, 2019, 208: 19-29.

[39] Liu S, Zhang C, Wang B, et al. Regulatory T cells promote glioma cell stemness through TGF-β-NF-κB-IL6-STAT3 signaling[J]. Cancer Immunol Immunother, 2021:2601-2616.

[40] Kuroda H, Mabuchi S, Yokoi E, et al. Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer[J]. Oncotarget, 2018, 9(91): 36317-36330.

[41] Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition[J]. Onco Targets Ther, 2018, 11: 3817-3826.

[42] Raggi C, Correnti M, Sica A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages[J]. J Hepatol, 2017, 66(1): 102-115.

[43] Okuda H, Kobayashi A, Xia B, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells[J]. Cancer Res, 2012, 72(2): 537-47.

[44] Chen Y, Wen H, Zhou C, et al. TNF-α derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt/β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells[J]. Exp Cell Res, 2019, 378(1): 41-50.

[45] Wei R, Zhu W, Yu G, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma[J]. Int J Cancer, 2021, 148(5): 1233-1244.

[46] Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity, 2014, 41(1): 49-61.

[47] Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease[J]. Nature, 2013, 496(7446): 445-55.

[48] Balkwill FR. The chemokine system and cancer[J]. J Pathol, 2012, 226(2): 148-57.

[49] Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity[J]. Immunity, 2000, 12(2): 121-7.

[50] Zhao R, Bei X, Yang B, et al. Endothelial cells promote metastasis of prostate cancer by enhancing autophagy[J]. J Exp Clin Cancer Res, 2018, 37(1): 221.

[51] Huang R, Guo L, Gao M, et al. Research trends and regulation of CCL5 in prostate Cancer[J]. Onco Targets Ther, 2021, 14: 1417-1427.

Funding

National Natural Science Foundation of China(82274512)

Guangzhou Science and Technology Project(202201020327)

Collaborative basic and clinical Innovation project between Guangdong Hospital of Chinese Medicine and the School of Biomedical Sciences of the Chinese University of Hong Kong(YN2018HK02)

Guangdong basic and Applied basic Research Fund(2023A1515110708)